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Abstract
Background: Ocular pathology lessens light's efficacy to maintain optimal circadian entrainment.
We examined whether ophthalmic dysfunction explains unique variance in melatonin excretion of
older adults over and above the variance explained by daily illumination, medical, and
sociodemographic factors. We also examined whether ophthalmic dysfunction influences
relationships between ambient illumination and melatonin.
Methods: Thirty older adults (mean age = 69 years; Blacks = 42% and Whites = 58%) of both
genders participated in the study. Demographic and health data were collected at baseline.
Participants underwent eye exams at SUNY Downstate Medical Center, wore an actigraph to
monitor illumination and sleep, and collected urine specimens to estimate aMT6s concentrations.
Results: Hierarchical regression analysis showed that illumination factors explained 29% of the
variance in aMT6s mesor. The proportion of variance explained by ophthalmic factors, sleep
duration, and race was 10%, 2%, and 2%, respectively. Illumination factors explained 19% of the
variance in aMT6s acrophase. The proportion of variance explained by ophthalmic factors, sleep
duration, and race was 11%; 17%; and 2%, respectively. Controlling for sleep duration and race
reduced the correlations between illumination and melatonin, whereas controlling for ophthalmic
factors did not.
Conclusion: Ophthalmic exams showed that elevated intraocular pressure and large cup-to-disk
ratios were independently associated with earlier melatonin timing. Lower illumination exposure
also had independent associations with earlier melatonin timing. Conceivably, ophthalmic and
illumination factors might have an additive effect on the timing of melatonin excretion, which in turn
might predispose individuals to experience early morning awakenings.
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Introduction
Light influences numerous biological and behavioral
functions [1-3]. In the laboratory, exposure to light of var-
ying intensities, wavelengths, and durations entrains the
circadian pacemaker [4], suppresses melatonin rhythms
[2,3,5], and modulates pupillary reflexes [6-8]. Recent evi-
dence suggests that these processes involve specialized sig-
nal transduction mechanisms of intrinsically
photosensitive retinal ganglion cells [9]. These cells are
believed to express melanopsin, the primary candidate
photopigment in the synchronization of circadian
rhythms [7,10-12].
Studies performed in the natural environment have
shown that ambient illumination affects melatonin
rhythms [13,14], rest-activity cycles [15,16], and mood
[17,18]. Naturalistic studies have also demonstrated that
several factors impinge on the level and timing of ambient
illumination. They include age [16], gender [19], race/eth-
nicity [15,19], time standard [16], season [20-23], and lat-
itude [20]. Notwithstanding the importance of these
factors, the integrity of the visual and photic system
remains the overriding component governing light's abil-
ity to entrain circadian rhythms.
Generally, blind patients without conscious light percep-
tion show a loss of circadian entrainment and do not
experience light-induced suppression of melatonin [2,24-
28]. Emerging evidence suggests, however, that a minority
of blind patients maintain the capacity for photic entrain-
ment, as demonstrated through melatonin-suppression
tests [2,25]. Thus, light transmission is not necessarily
abolished in all patients with no conscious light percep-
tion, particularly where no optic diseases are suspected. A
recent study, investigating adolescents and young adults
ages 12–20 years from the Missouri School for the Blind,
found significantly greater circadian dysfunction (e.g.,
more daytime napping and variable timing of awaken-
ing), among patients with optic diseases relative to those
without such diseases [29]. It appears that blind patients
exhibiting incapacity for photic entrainment represent a
unique category.
Much less is known regarding effects of age-related photic
impairment on circadian rhythm functions. There are sug-
gestions that several ophthalmic diseases could attenuate
photic transmission to the circadian pacemaker. Senile
miosis is one of those diseases; it is characterized by an
age-related reduction in pupil diameter that could reduce
retinal illumination [6,30]. Opacification and yellowing
of the crystalline lens of the eye, as seen in patients with
cataracts, can also substantially reduce photic transmis-
sion [31]. Loss of retinal ganglion cells, which afflicts pri-
marily glaucoma patients, might negatively affect retinal
phototransduction to the pacemaker [32,33].
It of great interest to ascertain how each of these ophthal-
mic diseases compromises light input to the circadian sys-
tem. Judging from the available evidence, it is reasonable
to hypothesize that age-associated ocular pathology less-
ens light's efficacy to maintain optimal circadian entrain-
ment [34-36]. In the present study, we tested the
hypothesis that ophthalmic dysfunction explains unique
variance in melatonin excretion of older adults over and
above that explained by daily illumination, medical, and
sociodemographic factors. A parallel hypothesis exam-
ined in this study was that ophthalmic dysfunction influ-
ences the relationships between ambient illumination
and endogenous melatonin rhythms.
Methods
Participants
Data presented in this paper were from a study investigat-
ing relations of ambient illumination to depression and
melatonin excretion. Associations of daily illumination
exposure with depression have been reported elsewhere
[18]. The present report focuses on relationships of daily
illumination and ophthalmic measures to melatonin
excretion.
Respondents to study advertisements completed baseline
questionnaires. They were included if they had no current
eye diagnosis, their self-stated race was Black or White,
were 60 years old or older, and provided informed con-
sent under the supervision of the Institutional Review
Boards at SUNY and UCSD. They were excluded if they
indicated major depression or lithium use, sleep apnea,
drugs that influence endogenous melatonin, a history of
ocular surgery or laser treatment, or impaired cognitive or
functional ability. Respondents were compensated for
participating in the study.
Volunteers meeting study criteria provided demographic
and health-related data, underwent eye exams, provided
illumination and sleep data, and collected urine speci-
mens. Thirty participants (mean age = 69.03 ± 6.84 years)
provided complete data for the present analyses. The sam-
ple comprised Black (43%) and White (57%) Americans
of both genders (women = 80% and men = 20%), with a
BMI averaging 26.89 ± 6.11 kg/m2; 87% received at least
a high school diploma and the median household income
was $16,500.
Procedures
Baseline data were acquired using the Comprehensive
Assessment and Referral Evaluation (CARE), the 30-item
Geriatric Depression Scale (GDS), and the Pittsburgh
Sleep Quality Index (PSQI). The CARE has been widely
used to assess physical health of older individuals in
minority communities. It has shown good construct valid-
ity [37] as well as concurrent and predictive validity [38].Journal of Circadian Rhythms 2005, 3:13 http://www.jcircadianrhythms.com/content/3/1/13
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Five sub-scales were included in the present analysis:
vision disorder, respiratory disease, diabetes, hyperten-
sion, and sleep disorder (Cronbach α = 0.78; 0.86; 0.82;
0.91; and 0.92, respectively).
The GDS measures depressed moods. It comprises five
main factors described as: sad mood, lack of energy, posi-
tive mood, agitation, and social withdrawal. According to
a study that examined depressed moods among adults (≥
60 years old) attending primary-care clinics, the GDS had
a sensitivity of 100% and a specificity of 84% in screening
for major depression, using a cut-off score of 10 [39]. By
contrast, the original psychometric study, which used a
cut-off score of 11, found a sensitivity of 81% and a spe-
cificity of 61% for major depression (DSMIII-R) [40].
Although the PSQI is not highly specific, it is a valid meas-
ure of subjective sleep quality in clinical research. A psy-
chometric study has shown good overall reliability
coefficient for the PSQI (Cronbach α = 0.77) [41]. When
investigators used a cut-off point of 5.5 in the global score,
sensitivity and specificity estimates were respectively
85.7% and 86.6% for primary insomnia, 80.0% and
86.6% for major depression, 83.3% and 86.6% for gener-
alized anxiety disorder, and 83.3% and 86.6% for schizo-
phrenia. Nonetheless, this scale does not necessarily
distinguish between conditions disturbing subjective
sleep.
Ophthalmic assessment
A trained technician performed standard examinations to
assess ophthalmic disorders. These provided data on vis-
ual acuity, visual field defects (mean deviation), intraocu-
lar pressure (IOP), vertical and horizontal cup-to-disk
ratios (CDR), and nerve-fiber-layer (NFL) thickness; a
large CDR is an indicator of glaucoma. An ophthalmolo-
gist graded ocular photos.
Snellen best-corrected visual acuity was obtained and con-
verted into logMAR units; higher scores denoted worse
visual acuity. The SITA standard program of the Hum-
phrey Field Analyzer was used for visual field testing to
estimate ocular nerve loss [42]. Results of the Ocular
Hypertension Treatment Study suggested that 97% of vis-
ual field examinations are reliable [43]. Tonometry was
used to assess intraocular pressure [44,45]. The Egna-Neu-
markt Glaucoma study revealed that the sensitivity and
specificity of tonometry in recognizing glaucoma are 80%
and 98%, respectively [44]. Fundus photography was used
to examine the retina and the macula [45]. Vertical and
horizontal CDR in the optic disk were derived, with
higher scores indicating greater abnormality. According to
the Early Treatment Diabetic Retinopathy Study, agree-
ment rates range from 78% to 83% between retinal spe-
cialists and photographic graders [46]. Peripapillary NFL
thickness, a measure of atrophy of the retinal ganglion
cells, was assessed with a scanning laser polarimeter
(Nerve Fiber Analyzer GDX) [47]. The GDX can detect
glaucomatous eyes with a sensitivity of 71% and a specif-
icity of 91% [48].
Illumination and sleep assessment
Upon completion of eye exams, participants wore the
Actiwatch-L (Mini Mitter Co., Inc.) for a week at home to
monitor ambient illumination and sleep. The Actiwatch-L
is a monitoring device worn on the wrist, which incorpo-
rates a photometer and a linear accelerometer. The pho-
tometer registers illumination that ranges from 1 to
150,000 lux. Registered lux values are averaged across
each minute and stored in memory.
Illumination time-series data were imported into a com-
puter program for least-squares cosine analyses using
Action3 software. This technique is preferred because it
corrects for biases due to the time of day when the record-
ings began and for missing data due to actigraph removal.
Cosine analyses were performed on the logarithm of
measured illumination. Derived circadian measures were:
1) the mesor, the fitted 24-hour average of logged illumi-
nation levels and 2) the acrophase, the timing of the peak
of the fitted cosine; goodness of fit for the cosines aver-
aged 0.65 ± 0.12. Acrophases could be linearized before
performing statistical analyses, since their distribution did
not cover the whole range of 360 degrees.
The accelerometer of the Actiwatch-L is sensitive to 0.01 g.
and has a sampling frequency of 32 Hz; it summates and
records the degree and intensity of motion on a minute-
by-minute basis. Actigraphic sleep time was estimated
using an automatic algorithm provided by the Actiwatch
manufacturer [49]. Acceptable correlations have been
found between actigraphic and polysomnographic esti-
mates of sleep duration, but the accuracy of the algorithm
has not been systematically ascertained for use among
older adults. Illumination and sleep log data were used to
verify time-in-bed intervals before estimating sleep and
wakefulness. Sleep duration was averaged across all seven
days, and this was used as a measure of habitual sleep
time.
Melatonin assessment
Urine samples were collected for approximately 24 hours
near the end of the Actiwatch-L recording. Participants
collected each fractional urine specimen, measured and
recorded its time and total volume, and froze duplicate
aliquots in two 2 cc vials. Most volunteers provided the
required 10 samples spanning at least 24 hours, and most
included at least one mid-sleep collection. Samples were
retrieved by a staff member and sent to UCSD where they
were stored at -70°C until assay of 6-sulfatoxymelatoninJournal of Circadian Rhythms 2005, 3:13 http://www.jcircadianrhythms.com/content/3/1/13
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(aMT6s), the major urinary melatonin metabolite using
96 well ELISA kits (Buhlmann Labs, EK-M6S) purchased
from ALPCO, Ltd. (Windham, NH). This is a competitive
immunoassay that uses a highly specific rabbit anti-6-sul-
fatoxymelatonin antibody and a second antibody capture
technique. Assay performance has been extensively vali-
dated by the manufacturer and results correlate well with
the Arendt (Stockgrand, Ltd) RIA (r = 0.987). At the usual
dilution of 1:200 the analytical sensitivity of the ELISA is
0.35 ng/ml and the functional least detectable dose (for
CV < 20%) is 1.3 ng/ml. In our laboratory, control urine
samples averaging 4–6 ng/ml give intra- and inter-assay
CVs of 4% and 7%, respectively.
To ensure reliability of the aMT6s data, we visually ana-
lyzed excretion curves of all participants to record an over-
all quality score for each 24-hour profile. This evaluation
was performed blind to all other information about the
participants and was mainly based on the shape and com-
pleteness of the ng/h curve, but agreement between ng/h
and ng/ml temporal patterns, smoothness of the baseline,
and reliability of the patient log were also considered. As
a circadian pattern that is clear and free of irregularities is
required to estimate acrophase reliably, onset, and offset,
profiles with poor quality scores were excluded. Accord-
ingly, we selected 30 suitable profiles from a total of 59
considered. Data excluded from the final batch were not
assayed due mostly to missing samples or inaccurate
record keeping. Volunteers providing complete melatonin
data were not significantly different in clinical presenta-
tion compared to those who did not. Of note, Blacks pro-
vided a greater number of unusable melatonin samples.
The aMT6s excretion rate for each urine sample was com-
puted and transformed into 5-min epoch data and the
resulting time series data were imported into Action3 soft-
ware (Ambulatory Monitoring Inc., Ardsley, NY), where
they were aligned with illumination data and further
checked for accuracy. Twenty-four-hour least-squares
cosine fits were computed for the full aMT6s collection
(average duration, excluding missing data intervals was
24.00 h) yielding aMT6s mesors and acrophases. To esti-
mate the duration of nocturnal aMT6s excretion, the onset
and the offset of the excretion were estimated by interpo-
lation of times at which the excretion rate (ng/h) crossed
the mesor level. The time of onset of aMT6s excretion was
estimated as the upward crossing and offset as the down-
ward crossing of the mesor level; aMT6s duration was
defined as the interval between onset and offset times.
Goodness of fit for the cosines averaged 0.81 ± 0.11.
Statistical analysis
All acquired data were merged into SPSS 10.0 for final
analyses. These included ophthalmic, sociodemographic,
medical, mood, illumination, sleep, and melatonin data.
Distributions were checked for normality and were trans-
formed where necessary using appropriate statistical tech-
niques. Frequency and measures of central tendency were
used to describe the sample. MANCOVA was used to
examine race effects on ophthalmic, illumination, sleep,
and melatonin measures. This procedure allowed correc-
tion for multicolinearity, if detected, and adjustment for
multiple comparisons.
To examine which factors were predictive of the depend-
ent variables: aMT6s mesor (fitted mean) and acrophase
(timing), we employed two hierarchical regression mod-
els. This statistical modeling technique yields the propor-
tion of variance in the dependent variable that can be
explained by an additional set of factors, over and above
that explained by the initial set. Accordingly, one can opt
to use the restricted model component, providing results
only for the initial set. One can also use the expanded
model, which sequentially analyzes the independent con-
tribution of additional sets. In the present analysis, the
initial set comprised the mesor and the acrophase of illu-
mination. Three other sets of factors: demographic, medi-
cal, and ophthalmic were entered in a stepwise manner.
Table 1: Values represent adjusted mean ± standard error of ophthalmic measures. Data obtained for visual acuity were converted 
into logMAR units. Intraocular pressure and horizontal and vertical cup-to-disk ratios were log-transformed. For visual field mean 
deviation and nerve-fiber-layer thickness, a z-transformation procedure was used. Values were adjusted for effects of age and gender.
MANCOVA: Race Effects on Ophthalmic Measures
Variable Black (mean ± SE) White (mean ± SE) F p
Visual Acuity (logMAR) -0.27 ± 0.07 -0.18 ± 0.06 0.872 0.359
Intraocular Pressure (mmHg) 1.25 ± 0.02 1.18 ± 0.02 4.991 0.034
Vertical Cup/Disk Ratio (mm2) -0.39 ± 0.06 -0.56 ± 0.05 6.090 0.020
Horizontal Cup/Disk Ratio (mm2) -0.44 ± 0.05 -0.60 ± 0.04 5.060 0.033
Visual Field Mean Deviation (dB) -0.52 ± 0.33 0.13 ± 0.27 2.064 0.163
Nerve-Fiber-Layer Thickness (µm) -0.36 ± 0.32 0.53 ± 0.28 4.011 0.056Journal of Circadian Rhythms 2005, 3:13 http://www.jcircadianrhythms.com/content/3/1/13
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The first regression model used aMT6s mesor as the
dependent variable and the illumination data plus three
sets of factors as predictors. In the second model, aMT6s
acrophase timing was used as the dependent variable, and
the above factors were entered as in the first model.
Factors in these analyses were chosen because of their
associations with the dependent measures and/or because
of their hypothesized connection to melatonin. The selec-
tion process was based on preliminary results of the Pear-
son and Spearman correlations that were run to examine
the magnitude of the correlation between each factor and
the dependent variables and by examination of their col-
linearity. Results of these preliminary analyses revealed
that race/ethnicity was the most important factor for the
sociodemographic set (i.e., age, sex, race, education, and
income). Of the medical set (BMI, hypertension, diabetes,
mood, sleep duration, and sleep quality), sleep duration
was chosen. Of the ophthalmic set (i.e., visual acuity, CDR
ratios, IOP, visual fields mean deviation, and NFL thick-
ness), IOP and horizontal CDR were selected; these two
factors were chosen because they showed similar coeffi-
cients and because of their theoretical importance as indi-
cators of glaucoma in the regression model.
To assess whether associations between illumination and
melatonin were mediated by ophthalmic factors, partial
correlations were used. In that analysis, the ophthalmic
factors were controlled. In separate partial correlation
analyses, effects of the demographic and medical factors
were controlled.
Results
Most participants (79%) were in good health. None were
legally blind, but 30% were visually impaired based on
standard criteria (best corrected vision worse than 20/40
and better than 20/200 in the better eye) [50]. Of the sam-
ple, 83% reported being satisfied with their sleep,
although 61% indicated either difficulty initiating sleep,
difficulty maintaining sleep, early morning awakening, or
daytime napping. Moreover, 23% reported a respiratory
condition, 60% hypertension, 77% arthritis, 43% vision
problems, and 14% diabetes. Fifty-two percent reported
social drinking, 15% indicated consumption of sleep aids,
and 7% were current smokers.
On average, volunteers had a GDS score of 7.07 ± 3.69
and a PSQI score of 4.68 ± 2.80. Subjective and acti-
graphic estimates of total sleep time averaged 6.40 ± 1.04
hours and 7.55 ± 1.74 hours, respectively. Median ambi-
ent illumination was 565.68 lux. Median aMT6s excretion
was 324.60 ng/h. The medians for the acrophases of illu-
mination and aMT6s were 14.12 hours and 3.18 hours
(after midnight), respectively. As seen in Table 1, race had
significant effects on ophthalmic measures, indicating
greater ophthalmic dysfunction for Blacks. In Table 2, we
present results of race effects on illumination, melatonin,
and sleep measures.
Analysis indicated that the mesor and the acrophase of
aMT6s were both associated with the sociodemographic,
medical, and ophthalmic factors. The multiple correlation
(r2) of aMT6s mesor to these factors added individually
was: [r2 = 0.24; r2 = 0.23; r2 = 0.15, respectively]; for aMT6s
acrophase, it was: [r2 = 0.15; r2 = 0.21; r2 = 0.28, respec-
tively]. However, in the interest of developing parsimoni-
ous regression models and because our sample was too
small for a detailed analysis of the overlapping effects of
all of the factors on the dependent variables, we selected
representative factors from each set of factors. Accord-
ingly, besides the mesor and acrophase of illumination
only race, sleep duration, CDR and IOP were entered into
the hierarchical regression models as predictors. With a
sample size of 30 and an alpha value set at 0.05, it was
determined a priori that the study would have power of
0.85 to construct a reliable model with six predictors,
accounting for 41% of the variance in the dependent var-
iable.
Table 2: Adjusted mean values ± standard error for illumination (lux), melatonin (aMT6s), and sleep measures. Values were adjusted 
for effects of age and gender.
MANCOVA: Race Effects on Illumination, Melatonin, and Sleep
Variable Black (mean ± SE) White (mean ± SE) F p
Light Mesor [log] 1.03 ± 0.10 1.38 ± 0.08 6.033 0.022
Light Phase [hr] 13.57 ± 0.34 14.54 ± 0.27 4.306 0.049
aMT6s Mesor [log] 2.67 ± 0.14 2.31 ± 0.11 3.311 0.082
aMT6s Phase [hr, after midnight] 2.35 ± 0.37 3.45 ± 0.29 4.745 0.040
Phase Angle Between aMT6s and Sleep Timing [hr] 2.55 ± 0.43 2.25 ± 0.29 0.305 0.586
Mid-Sleep [hr] 4.76 ± 0.34 5.51 ± 0.27 2.580 0.122
Sleep Duration [hr] 5.75 ± 0.28 6.57 ± 0.21 4.800 0.039Journal of Circadian Rhythms 2005, 3:13 http://www.jcircadianrhythms.com/content/3/1/13
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Results of the first hierarchical regression analysis showed
that illumination factors explained 29% of the variance in
aMT6s mesor; illumination acrophase was the main con-
tributor, indicating that individuals showing later timing
had lower aMT6s mesors. Sequential addition of the other
factors (i.e., CDR and IOP, entered as a set, sleep duration,
and race) showed that the proportion of variance
explained by each was 10%, 2%, and 2%, respectively.
Overall, the expanded model accounted for 43% of the
variance in aMT6s mesor [F = 3.47, p < 0.05]. The adjusted
stepwise correlations of each of the factors to aMT6s
mesor were: illumination mesor [rp = -0.08], illumination
acrophase [rp = -0.49], race [rp = -0.08], sleep duration [rp
= -0.25], IOP [rp = 0.31], and CDR [rp = -0.25]. For each of
these correlations, effects of the other five factors were
simultaneously adjusted.
In the second hierarchical regression analysis, where
aMT6s acrophase was the dependent variable, the illumi-
nation factors explained 19% of the variance; individuals
receiving greater daily illumination level and showing
later illumination timing were likely to show later aMT6s
timing. The proportion of variance explained by the fac-
tors: CDR and IOP (entered as a set), sleep duration, and
race was 11%; 17%; and 2%, respectively. Altogether, the
expanded model accounted for 49% of the variance in
aMT6s acrophase [F = 2.64, p < 0.05]. The adjusted step-
wise correlations of each of the factors to aMT6s acro-
phase were: illumination mesor [rp = 0.41], illumination
acrophase [rp = 0.09], race [rp = -0.03], sleep duration [rp =
0.48], IOP [rp = -0.29], and CDR [rp = -0.32].
In Table 3, we present results of the partial correlation
analyses, examining associations of illumination factors
with melatonin measures. Consistent with regression
results, later timing of illumination was significantly asso-
ciated with lower aMT6s mesor. Controlling for sleep
duration and race somewhat reduced this association,
whereas controlling for IOP and CDR affected them little.
Trends suggested that greater illumination was associated
with later aMT6s timing.
Discussion
The data show that ophthalmic dysfunction was associ-
ated with the endogenous melatonin rhythms of commu-
nity-residing older adults. Ophthalmic factors explained a
significant proportion of the variance in 24-hr 6-sulpha-
toxymelatonin excretion (mesor) and timing (acrophase),
over and above the variance explained by daily illumina-
tion, sleep duration, and race. Although most of the vol-
unteers were in good health, ophthalmic exams showed
significant evidence of photic impairment anchored by
elevated intraocular pressure and large cup-to-disk ratios,
which were independently associated with earlier mela-
tonin timing. We observed that lower illumination levels
also had independent associations with earlier melatonin
timing. Conceivably, ophthalmic and illumination factors
might have an additive effect on the timing of melatonin
excretion, which in turn might predispose individuals to
experience early morning awakenings.
As greater intraocular pressure and cup-to-disk ratio may
be indicative of optic nerve loss, a common finding
among glaucoma patients [32], their effects on melatonin
rhythms might be mediated by a defect in retinohypotha-
lamic stimulation. Unfortunately, this study did not offer
direct support for this hypothesis. Ophthalmic dysfunc-
tion does not seem to have a mediating effect on the rela-
tionships between ambient illumination and melatonin
rhythms, as these relationships remained virtually
unchanged when we controlled for differences in ophthal-
mic factors. Hence, abnormalities in both IOP and CDR
Table 3: Values represent correlation coefficients (Coef.) for associations of ambient illumination with melatonin measures from three 
separate analyses. First, Pearson correlations were run with no control for the covariates. Second, partial correlations were run with 
control for sleep duration and race. Third, partial correlations were run with control for intraocular pressure (IOP) and cup-to-disk 
ratio (CDR).
Relationships Between Illumination and Melatonin
aMT6s Mesor aMT6s Phase
Variable Coef. p Coef. p
No control [r] Light Mesor 0.07 0.73 0.31 0.09
Light Phase -0.50 0.01 0.18 0.35
Control for sleep and race [rp] Light Mesor 0.19 0.35 0.28 0.16
Light Phase -0.43 0.03 0.03 0.88
Control for IOP and CDR [rp] Light Mesor 0.07 0.71 0.22 0.25
Light Phase -0.49 0.01 0.08 0.61Journal of Circadian Rhythms 2005, 3:13 http://www.jcircadianrhythms.com/content/3/1/13
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may have had a direct effect on the timing of melatonin
excretion of White and Black participants. However, asso-
ciations of IOP and CDR with the amount of melatonin
excretion were mixed, with greater IOP predicting greater
excretion while greater CDR predicted lower excretion
rates, which was in the expected direction. This discrep-
ancy merits further examination, but we might consider
that previous studies of melatonin rhythms in uncon-
trolled environments have shown that the acrophase,
rather than the mesor of melatonin excretion, strongly
correlated to ambient illumination [13], depression
scores [51], activity rhythms [52], napping behavior [53],
and duration and timing of sleep [52,54].
Habitual illumination pattern was the best predictor of
aMT6s rhythms of all the factors in the regression models.
Both brighter and later illumination exposure correlated
to later aMT6s timing, although illumination level was a
better predictor in the regression model. We noted that
the timing of illumination exposure, rather than its
mesor, correlated significantly to the mesor of aMT6s. It
might be that a later illumination acrophase reflects less
illumination exposure in the morning before the endog-
enously timed offset of melatonin secretion. Therefore, a
later illumination acrophase might be associated with less
morning light suppression of melatonin and, in turn, a
delayed acrophase of aMT6s excretion.
The timing of daily illumination might be a better index
of the amount of aMT6s excretion, irrespective of individ-
uals' sociodemographic and medical characteristics. Evi-
dently, this must be balanced against the observation that
the timing of melatonin excretion can be influenced by
age-related weakening of the circadian pacemaker as well
as by individual preferences in the timing of outdoor day-
light activities [55-57]. Other factors influencing mela-
tonin excretion in the natural setting include day length,
age, duration and timing of sleep, and usage of certain
medications [13,16,19,23,58]. Our analysis considered
the relative contribution of all these factors, except for day
length (season), but scheduling of the recordings was bal-
anced across seasons throughout the study period.
Sleep duration is another factor that played an important
role in the analyses. That sleep duration correlated with
both the mesor and the acrophase of aMT6s is consistent
with previous findings [59-61]. We would have expected
that shorter sleep duration would correlate with reduced
aMT6s excretion, as predicted by data suggesting a longer
experience of nocturnal darkness (as might be associated
with a longer sleep duration) results in a longer duration
of melatonin excretion [62]. The inverse correlation
found in our study may have been influenced by the find-
ing that Blacks slept less than did Whites while showing
greater mesors of aMT6s excretion. It is noteworthy that in
our preliminary analyses aMT6s measures had stronger
correlations to sleep duration than to a history of hyper-
tension, diabetes, or respiratory disease, BMI, mood or
sleep quality. Possibly, sleep duration is a proxy for these
measures, as it correlates to each, albeit to varying degrees.
Of all the sociodemographic factors we analyzed, race was
the strongest correlate of aMT6s measures. This is consist-
ent with results of the analysis of covariance reported in
Table 2. Independent of individuals' age and gender, race
had significant effects on the melatonin measures. Simi-
larly, race had significant effects on the ophthalmic, illu-
mination, and sleep variables. These findings evidence
that race is an important factor when analyzing sleep and
circadian rhythm measures. Notwithstanding, it is less
robust than the illumination, sleep, and ophthalmic fac-
tors in explaining the variance in aMT6s measures. One
explanation for the reduced significance of race in the
regression models relates to the shared variance in aMT6s
measures explained by both race and these other factors.
Consistent with previous epidemiological and clinical
data, individuals of the Black race showed worse scores on
ophthalmic exams [63,64]. A thinner nerve fiber layer, an
elevated intraocular pressure, and greater cup-to-disk
ratios, as observed among Blacks, are three important
indicators of optic nerve loss in glaucoma. One implica-
tion of these findings is that since glaucoma is more com-
mon among Blacks [65,66], they may be at increased risks
of developing circadian abnormalities through reduction
of photic transduction to the circadian pacemaker.
Since we used a relatively small sample size, we could not
assess the overlapping effects of all the independent fac-
tors on melatonin rhythms. It was evident that daily illu-
mination, ophthalmic factors, sleep duration, and race
each had independent associations with both the mesors
and acrophases of melatonin excretion. Although our
regression models approximated predictions of the power
analysis, they warrant replication in a larger sample.
Efforts should be made to provide detailed instructions in
gathering melatonin samples among minority groups.
The observation that Blacks had lower illumination expo-
sure, greater ophthalmic dysfunction, and higher aMT6s
levels merits further empirical study, as these characteris-
tics are suggestive of depressed moods [18,51,58,67].
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